annual operating expenses:
$304.43M+$5.11M(+1.71%)Summary
- As of today (June 22, 2025), HALO annual total operating expenses is $304.43 million, with the most recent change of +$5.11 million (+1.71%) on December 31, 2024.
- During the last 3 years, HALO annual operating expenses has risen by +$218.44 million (+254.01%).
- HALO annual operating expenses is now at all-time high.
Performance
HALO Operating expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly operating expenses:
$74.92M-$5.53M(-6.87%)Summary
- As of today (June 22, 2025), HALO quarterly total operating expenses is $74.92 million, with the most recent change of -$5.53 million (-6.87%) on March 31, 2025.
- Over the past year, HALO quarterly operating expenses has increased by +$2.92 million (+4.05%).
- HALO quarterly operating expenses is now -11.19% below its all-time high of $84.36 million, reached on June 30, 2022.
Performance
HALO quarterly operating expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Operating expenses Formula
Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses
HALO Operating expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +1.7% | +4.0% |
| 3 y3 years | +254.0% | +191.7% |
| 5 y5 years | +39.6% | +228.8% |
HALO Operating expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +254.0% | -11.2% | +191.7% |
| 5 y | 5-year | at high | +280.7% | -11.2% | +320.8% |
| alltime | all time | at high | >+9999.0% | -11.2% | +7356.5% |
HALO Operating expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $74.92M(-6.9%) |
| Dec 2024 | $304.43M(+1.7%) | $80.45M(+3.9%) |
| Sep 2024 | - | $77.46M(+4.0%) |
| Jun 2024 | - | $74.51M(+3.5%) |
| Mar 2024 | - | $72.01M(-6.1%) |
| Dec 2023 | $299.32M(+18.2%) | $76.71M(+5.2%) |
| Sep 2023 | - | $72.93M(-4.7%) |
| Jun 2023 | - | $76.51M(+4.6%) |
| Mar 2023 | - | $73.17M(+12.8%) |
| Dec 2022 | $253.28M(+194.5%) | $64.87M(-17.2%) |
| Sep 2022 | - | $78.36M(-7.1%) |
| Jun 2022 | - | $84.36M(+228.4%) |
| Mar 2022 | - | $25.69M(+7.6%) |
| Dec 2021 | $86.00M(+7.5%) | $23.88M(+10.3%) |
| Sep 2021 | - | $21.66M(+6.2%) |
| Jun 2021 | - | $20.39M(+1.6%) |
| Mar 2021 | - | $20.07M(+12.7%) |
| Dec 2020 | $79.97M(-63.3%) | $17.81M(-8.4%) |
| Sep 2020 | - | $19.45M(-2.4%) |
| Jun 2020 | - | $19.93M(-12.6%) |
| Mar 2020 | - | $22.79M(-67.0%) |
| Dec 2019 | $218.06M(+3.3%) | $69.04M(+42.5%) |
| Sep 2019 | - | $48.43M(-5.5%) |
| Jun 2019 | - | $51.25M(+3.9%) |
| Mar 2019 | - | $49.33M(-9.8%) |
| Dec 2018 | $211.06M(+3.2%) | $54.68M(+8.5%) |
| Sep 2018 | - | $50.40M(-7.4%) |
| Jun 2018 | - | $54.44M(+5.6%) |
| Mar 2018 | - | $51.53M(-8.2%) |
| Dec 2017 | $204.46M(+3.9%) | $56.15M(+18.6%) |
| Sep 2017 | - | $47.32M(-8.0%) |
| Jun 2017 | - | $51.44M(+3.8%) |
| Mar 2017 | - | $49.55M(-7.5%) |
| Dec 2016 | $196.69M(+47.6%) | $53.58M(+17.8%) |
| Sep 2016 | - | $45.46M(-2.8%) |
| Jun 2016 | - | $46.75M(-8.2%) |
| Mar 2016 | - | $50.91M(+32.8%) |
| Dec 2015 | $133.26M(+15.2%) | $38.34M(+1.3%) |
| Sep 2015 | - | $37.84M(+22.0%) |
| Jun 2015 | - | $31.01M(+18.9%) |
| Mar 2015 | - | $26.08M(-7.1%) |
| Dec 2014 | $115.64M(-10.3%) | $28.08M(-1.4%) |
| Sep 2014 | - | $28.49M(+4.0%) |
| Jun 2014 | - | $27.40M(-13.5%) |
| Mar 2014 | - | $31.66M(+4.6%) |
| Dec 2013 | $128.99M | $30.28M(-10.5%) |
| Sep 2013 | - | $33.82M(-4.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2013 | - | $35.29M(+19.3%) |
| Mar 2013 | - | $29.59M(+15.8%) |
| Dec 2012 | $94.86M(+25.4%) | $25.55M(+1.6%) |
| Sep 2012 | - | $25.14M(+16.0%) |
| Jun 2012 | - | $21.66M(-3.8%) |
| Mar 2012 | - | $22.51M(+8.3%) |
| Dec 2011 | $75.67M(+13.1%) | $20.78M(+16.9%) |
| Sep 2011 | - | $17.78M(-10.7%) |
| Jun 2011 | - | $19.91M(+15.8%) |
| Mar 2011 | - | $17.19M(-16.4%) |
| Dec 2010 | $66.90M(-6.9%) | $20.57M(+30.0%) |
| Sep 2010 | - | $15.82M(+3.5%) |
| Jun 2010 | - | $15.28M(+0.4%) |
| Mar 2010 | - | $15.22M(-19.7%) |
| Dec 2009 | $71.82M(+22.0%) | $18.96M(+12.4%) |
| Sep 2009 | - | $16.87M(-8.7%) |
| Jun 2009 | - | $18.46M(+5.4%) |
| Mar 2009 | - | $17.53M(-12.2%) |
| Dec 2008 | $58.87M(+85.6%) | $19.96M(+47.5%) |
| Sep 2008 | - | $13.53M(+5.9%) |
| Jun 2008 | - | $12.77M(+1.3%) |
| Mar 2008 | - | $12.60M(+12.2%) |
| Dec 2007 | $31.71M(+96.6%) | $11.24M(+22.2%) |
| Sep 2007 | - | $9.19M(+42.2%) |
| Jun 2007 | - | $6.47M(+34.3%) |
| Mar 2007 | - | $4.81M(-4.7%) |
| Dec 2006 | $16.13M(+18.3%) | $5.05M(+31.9%) |
| Sep 2006 | - | $3.83M(+8.9%) |
| Jun 2006 | - | $3.52M(-5.5%) |
| Mar 2006 | - | $3.72M(+3.0%) |
| Dec 2005 | $13.64M(+50.1%) | $3.61M(-4.4%) |
| Sep 2005 | - | $3.78M(+27.3%) |
| Jun 2005 | - | $2.97M(-9.2%) |
| Mar 2005 | - | $3.27M(+29.4%) |
| Dec 2004 | $9.09M(>+9900.0%) | $2.53M(-22.5%) |
| Sep 2004 | - | $3.26M(+56.2%) |
| Jun 2004 | - | $2.09M(+73.0%) |
| Mar 2004 | - | $1.21M(-217.0%) |
| Dec 2003 | $0.00(0.0%) | -$1.03M(-352.9%) |
| Sep 2003 | - | $408.20K(+9.5%) |
| Jun 2003 | - | $372.90K(+48.3%) |
| Mar 2003 | - | $251.40K(-532.7%) |
| Dec 2002 | $0.00(-100.0%) | -$58.10K(-326.1%) |
| Sep 2002 | - | $25.70K(+38.2%) |
| Jun 2002 | - | $18.60K(+35.8%) |
| Mar 2002 | - | $13.70K |
| Dec 2001 | $48.50K | - |
FAQ
- What is Halozyme Therapeutics annual total operating expenses?
- What is the all time high annual operating expenses for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual operating expenses year-on-year change?
- What is Halozyme Therapeutics quarterly total operating expenses?
- What is the all time high quarterly operating expenses for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly operating expenses year-on-year change?
What is Halozyme Therapeutics annual total operating expenses?
The current annual operating expenses of HALO is $304.43M
What is the all time high annual operating expenses for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual total operating expenses is $304.43M
What is Halozyme Therapeutics annual operating expenses year-on-year change?
Over the past year, HALO annual total operating expenses has changed by +$5.11M (+1.71%)
What is Halozyme Therapeutics quarterly total operating expenses?
The current quarterly operating expenses of HALO is $74.92M
What is the all time high quarterly operating expenses for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly total operating expenses is $84.36M
What is Halozyme Therapeutics quarterly operating expenses year-on-year change?
Over the past year, HALO quarterly total operating expenses has changed by +$2.92M (+4.05%)